Report Description of the Canada Dermatology Treatment Drugs Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for Canada Dermatology Treatment Drugs Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Canada Dermatology Treatment Drugs Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

Canada Dermatology Treatment Drugs Market Analysis Executive Summary

North America holds a large share of the market and this trend is expected to continue during the forecast period owing to the increasing awareness about potential applications of dermatology drugs, easy availability of dermatological, surge in incidences of skin disorders such as dermatitis, acne, and psoriasis. Technological advancements and increasing ageing population fuel the market in the region.

Market Size and Key Findings

The Canada Dermatology Treatment Drugs Market Analysis size stood at around USD xx% billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.



Market Dynamics

Market Growth Drivers Analysis

Canadas market is majorly driven by the rising burden of dermatology diseases. The skincare market is driven by the consumer attitude that is, to improve their quality of life in terms of looks and this attitude is visible across all the age groups. The Growing demand for anti-aging products and innovative and eco-friendly packaging designs are attributing to the market growth in the country. Canadas skin allergy market is forecasted to grow by 3.9% over the 2020-2028 period. The extensive presence of online retail channels is also influencing sales of cosmetics in the country. The collective incidence of dermatological diseases and increasing levels of awareness-related disease progression, Etiology, and available therapies are leading to the high growth of dermatological therapeutics.

Market Restraints

Serious side effects of certain classes of therapeutic drugs are expected to restrain the market growth in the near future. Moreover, Stringent Regulations for Dermatology Drugs and High Cost of Dermatology Drugs are assumed to be restraining the North America Dermatology Drugs Market.

Covid-19 Market Impact Analysis

The COVID-19 pandemic has had a significant impact on the healthcare system. It has reduced the growth rate of the market due to the rapid shift in focus toward COVID-19 treatment. As a result, the majority of the hospitals have delayed vaccinations pertaining to dermatology, chemotherapy sessions, and other non-essential services.

Competitive Landscape

Key Players

Players operating in the global dermatology drugs market include Lupin, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi, GlaxoSmithKline plc, Amgen Inc., Eli Lilly and Company, AstraZeneca, AbbVie Inc, Johnson & Johnson Services. Inc, Galderma laboratories L.P., LEO Pharma A/S, Merck & Co., Inc, Bausch Health, and Bristol-Myers Squibb Company.

Products in Pipeline

• The acquisition of Eli Lilly and company & Dermira company will expand the pipeline of Lilly's immunology with the addition of lebrikizumab which is a new monoclonal antibody designed to treat atopic dermatitis. This acquisition also expands the company portfolio of marketed dermatology medicines with the addition of QBREXZA (glycopyrronium).

Notable Recent Deals

• In November 2018, Sanofi collaborated with Denali Therapeutics Inc. (Denali), a biopharmaceutical company, for the development of multiple molecules, DNL747 and DNL758, with the potential to treat a range of neurological and systemic inflammatory diseases.


• In April 2019, LEO Pharma announced the expansion of its existing partnership with Elektrofi for the development of convenient system for dermatology treatments. This is expected to reduce the time required for the treatment.


• In January 2020, Eli Lilly and Company announced that they have acquired Dermira, which is a biopharmaceutical company engaged in the introduction of novel therapies to treat the chronic skin conditions in a much better way.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The Canadian Dermatology Association, founded in 1925, represents Canadian dermatologists. The association exists to advance the science and art of medicine and surgery related to the care of the skin, hair and nails; provide continuing professional development for its members; support and advance patient care; provide public education on sun protection and other aspects of skin health; and promote a lifetime of healthier skin, hair and nails.

The mission of the Canadian Hidradenitis Suppurativa Foundation is to improve the daily life and quality of care for Canadians living with Hidradenitis Suppurativa through education, research and patient empowerment.

The Canadian Working Group of Rheumatologists and Dermatologists (CARD) is supported by the Canadian Dermatology Association. It functions independently and does not report to the CDA Board of Directors.

Camp Libert is an independent, charitable organization created by a group of dermatologists dedicated to offering children an opportunity to enjoy a summer camp experience. The camp lasts six days and is open to children from across Canada who have moderate to severe skin conditions. The Canadian Professors of Dermatology (CPD) provides a forum for the discussion of all levels and aspects of dermatologic education in an informational and collegial setting. The CPD offers two programs during the year; DRIVE (Dermatology Residents Innovation & Vision in Education) and BoSS (Basics of Skin Science).

Initiatives taken by government and private organizations to develop pharmaceutical industry propel the growth of the market. However, the presence of alternative for acne treatment such as light or lasers therapies, chemical peels, micro needling, micro dermabrasion, and lesion removal is expected to restrict the dermatologicals market growth during the forecast period.